Compositions and Methods for Treating Neurologic Disorders
AssigneePalupa Medical Ltd.
InventorsMarios Pantzaris, Ioannis Patrikios, Georgios Loukaidis
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions comprising DHA, EPA, LA and GLA. The compositions may further comprise other omega-3 PUFAs, MUFAs, SFAs, gamma tocopherol, Vitamin A and Vitamin B. The compositions are useful for treating neurologic disorders. The compositions are administered chronically for the prevention and/or treatment of multiple sclerosis (MS) and other degenerative diseases.
Claims30
A liquid oral pharmaceutical composition, comprising
- a long chain polyunsaturated fatty acid (PUFA) fraction, comprising eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), linoleic acid (LA) and gamma linolenic acid (GLA);
- one or more other omega-3 PUFAs;
- and
- one or more monounsaturated fatty acid (MUFA).
A liquid oral pharmaceutical composition, comprising:
- (a) about 1650 mg EPA;
- (b) about 4650 mg DHA;
- (c) about 3850 mg LA;
- (d) about 5850 mg GLA;
- (e) about 760 mg gamma-tocopherol, and
- (f) about 22 mg Vitamin E.
A liquid oral pharmaceutical composition, comprising:
- a. EPA about 1650 mg/dose
- b. DHA about 4650 mg/dose
- c. GLA about 2000 mg/dose
- d. LA about 3850 mg/dose
- e. Other omega-3 PUFAs about 600 mg/dose, comprising:
- i. Alpha˜linolenic acid (C18:3n-3) about 37 mg/dose
- ii. Stearidonic acid (C18:4n-3) about 73 mg/dose
- Eicosatetraenoic acid (C20:4n-3) about 98 mg/dose
- iv. Docosapentaenoic acid (C22:5n˜3) about 392 mg/dose
- f. MUFAs, comprising:
- i. 18:1—about 1300 mg/dose
- ii. 20:1—about 250 mg/dose
- iii. 22:1—about 82 mg/dose
- iv. 24:1—about 82 mg/dose
- g. SFAs, comprising:
- i. 18:0—about 160 mg/dose
- ii. 16:0—about 650 mg/dose
- h. Vitamin A about 0.6 mg/dose
- i. Vitamin E about 22 mg/dose
- j. Gamma-tocopherol about 760 mg/dose
A method of treating or preventing a neurodegenerative disease in a human subject in need of therapy, comprising administering to the subject an effective amount of a liquid pharmaceutical composition, comprising:
- (a) about 500 mg to about 5000 mg EPA;
- (b) about 1000 mg to about 12000 mg DHA;
- (c) about 1000 mg to about 10600 mg LA;
- and
- (d) about 1000 mg to about 16000 mg GLA.
Dependencies are inferred from the claim text.